The following is a summary of “Association between incretin-based drugs and risk of cholangiocarcinoma among patients with ...

Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

For the first time in over a decade, obesity rates have dropped in the United States. A recent study by the CDC showed that ...

Digital technologies loom large on the list—from the growing impact of artificial intelligence to the need for tech-enabled ...

Positive results from clinical trials often give biotechnology companies a boost, but this one was big. Shares of Sana Biotechnology —a firm with a market capitalization of less than $400 million as ...

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

Months after posting weight loss of 7.5% at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just ...

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

(Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) For those who are overweight or obese, medications known as glucagon-like peptide-1 agonists, or GLP-1s, have become very ...

Highlight:,GLP-1 receptor agonists, like Ozempic and Wegovy, initially developed for diabetes and obesity, are now showing promise in treating a range of conditions including cardiovascular disease, ...

Already, GLP-1 weight ... and Eli Lilly’s drug is more potent, and perhaps negotiations with national health services will also make it more cost-effective than Wegovy.” The list price of ...